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Abstract
In human somatic tumorigenesis, mutations are thought to arise sporadically in individual cells surrounded by unaffected
cells. This contrasts with most current transgenic models where mutations are induced synchronously in entire cell
populations. Here we have modeled sporadic oncogene activation using a transgenic mouse in which c-MYC is focally
activated in prostate luminal epithelial cells. Focal c-MYC expression resulted in mild pathology, but prostate-specific
deletion of a single allele of the Pten tumor suppressor gene cooperated with c-MYC to induce high grade prostatic
intraepithelial neoplasia (HGPIN)/cancer lesions. These lesions were in all cases associated with loss of Pten protein
expression from the wild type allele. In the prostates of mice with concurrent homozygous deletion of Pten and focal c-MYC
activation, double mutant (i.e. c-MYC+;Pten-null) cells were of higher grade and proliferated faster than single mutant (Pten-
null) cells within the same glands. Consequently, double mutant cells outcompeted single mutant cells despite the presence
of increased rates of apoptosis in the former. The p53 pathway was activated in Pten-deficient prostate cells and tissues, but
c-MYC expression shifted the p53 response from senescence to apoptosis by repressing the p53 target gene p21
Cip1.W e
conclude that c-MYC overexpression and Pten deficiency cooperate to promote prostate tumorigenesis, but a p53-
dependent apoptotic response may present a barrier to further progression. Our results highlight the utility of inducing
mutations focally to model the competitive interactions between cell populations with distinct genetic alterations during
tumorigenesis.
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Introduction
Prevailing models of multistep carcinogenesis posit that
oncogenic mutations arise in isolated cells in situ followed by
clonal expansion. This implies that important competitive
interactions occur between mutant and normal cells as well as
between cells with distinct oncogenic mutations during tumori-
genesis. A detailed understanding of these interactions will further
efforts aimed at therapeutic targeting of neoplastic and preneo-
plastic lesions. However, these interactions have not been well
studied in vivo due to a paucity of appropriate models. We report
here our attempt to model these interactions in a new transgenic
model of prostate cancer, focusing on the oncogene c-MYC and
the tumor suppressor Pten (Phosphatase and tensin homolog), both
of which are implicated in human prostate tumorigenesis [1]. c-
MYC overexpression is a common early event in prostate cancer
[2,3] while PTEN is deleted/mutated in ,30% of primary human
prostate cancers [4–8]. Previous attempts at modeling c-MYC
overexpression in the mouse prostate have used prostate-specific
promoters that target transgene expression to a majority of the
cells in the prostatic epithelium. Depending on the strength of the
promoter used, this resulted in various grades of mouse prostatic
intraepithelial neoplasia (mPIN) or adenocarcinoma [3,9]. Simi-
larly, Pten-mutant mice develop mPIN and prostate cancer [10–
13] and Pten inactivation can cooperate with mutations in
oncogenes and tumor suppressors in prostate tumorigenesis,
including p27
Kip1 [14,15], Trp53 [13] and Fgf8b [16].
Pten loss has been reported to activate the p53 pathway, leading
to senescence [13,17,18]. Activation of p53 may lead to cell cycle
arrest or apoptosis depending on the downstream target genes
induced (i.e. cell cycle arrest genes e.g. p21
cip1 versus apoptotic
genes e.g. PUMA). There is potential cross-talk between the c-
MYC and the p53 pathways at various levels depending on the cell
context [19]. c-MYC activation can increase ARF expression,
thereby stabilizing p53 protein levels [20], and c-MYC can repress
expression of some p53 target genes such as p21
Cip1 [21]. In
addition, Pten and p53 coordinately control c-Myc protein levels
with the latter playing a critical role in maintaining the stemness of
murine neural stem cells [22].
To model the sporadic genetic alterations that arethought to occur
during human somatic tumorigenesis [23], we generated a transgenic
mouse in which a latent c-MYC transgene can be focally activated in
the prostatic epithelium by Cre expression. We have also deleted one
or both copies of Pten in the prostate concurrently with focal c-MYC
overexpression, in order to examine the interactions of cell
populations with distinct mutations within the same gland.
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Generation of PbCre4;Z-MYC mice with focal, prostate-
specific c-MYC overexpression
To target focal c-MYC expression in the prostate epithelium,
we used Z-MYC mice that carry a single copy transgene in which
the CMV enhancer/beta actin promoter drives expression of the beta-geo
gene and a latent c-MYC transgene [24] (Figure 1A). Staining for
beta-galactosidase confirmed mosaic expression in the prostate
epithelium (Figure 1A). To induce c-MYC expression focally in the
prostate, we crossed Z-MYC mice to PbCre4 mice [25] which
express Cre recombinase in the prostatic epithelium (Figure 1A).
Bigenic PbCre4;Z-MYC mice expressed c-MYC focally in cytoker-
atin 8 (CK8) positive prostate luminal epithelial cells but not p63+
basal cells (Figure 1C). Furthermore, c-MYC expression is not
abrogated in castrated animals indicating that the use of the CMV
enhancer/beta actin promoter in our model has uncoupled prostate-
specific expression from androgen-dependent gene regulation
(Figure 1B).
Mild pathology due to focal c-MYC overexpression
Focal c-MYC activation resulted in mild pathology, with most
prostates showing normal histology or low grade mPIN (LGPIN)
lesions up to 2 years of age (Figure 2A and 2B). This is unlikely to
be due to low level c-MYC expression as the CMV enhancer/beta
actin promoter is known to drive high level transgene expression. A
closer examination of the c-MYC expression pattern in the
prostates of PbCre4;Z-MYC mice with no pathology showed that in
young mice, the frequency of c-MYC-positive cells was ,18% of
the epithelial cells in c-MYC-positive glands (Figure 3G), evocative
of the frequency of LacZ-positive cells (,17%) in Z-MYC prostates
(Figure 1A). By 1 year, the frequency of c-MYC positive cells has
increased to ,43% (Figure 3G). The lack of discernible
histological abnormality in the prostates of a large fraction of
older PbCre4;Z-MYC mice in the face of abundant c-MYC
expression is reminiscent of the phenomenon of ‘‘field canceriza-
tion’’ in human tumorigenesis where incipient mutant cells occupy
tissue fields without any apparent pathology (Figure 3A–3F) [26].
These histologically normal but mutant cells may serve as targets
for transformation with additional genetic mutations.
Focal c-MYC expression cooperates with Pten
heterozygosity
Next, we generated compound mutant mice with prostate-
specific deletion of one or both alleles of Pten concurrently with
focal activation of c-MYC. Examination of PbCre4;Z-MYC;Pten
f/+
prostates revealed clear cooperation between c-MYC overexpres-
sion and Pten heterozygosity (Figure 2). As reported previously
[10,11] and confirmed by us here, conditional deletion of a single
Pten allele had little effect on the prostate with mice up to 50 weeks
of age showing minimal abnormalities (Figure 2A and 2B). By ,10
weeks of age however, PbCre4;Z-MYC;Pten
f/+ mice already have
evidence of focal HGPIN lesions. Over time, these animals
develop micro-invasive cancer as confirmed by the presence of
areas with disruption in smooth muscle actin (SMA) immunore-
activity (Figure 2B and 2C). We used immunohistochemistry to
examine the status of the wild type Pten allele in the HGPIN/
cancer lesions in PbCre4;Z-MYC;Pten
f/+ mice. Consistently, all
lesions examined (N=8 mice) showed loss of Pten protein
expression and phosphorylation of its downstream signaling
components Akt and Foxo1 [27] (Figure 4).
c-MYC+;Pten-null cells outcompete Pten-null cells in the
same glands
We analyzed proliferation by staining for phospho-histone H3
(pHH3), a mitotic marker. Proliferation was increased significantly
in PbCre4;Z-MYC prostates relative to controls, and Pten hetero-
zygosity synergistically increased it further (Figure 5A). The
proliferation rates in PbCre4;Pten
f/f and PbCre4;Z-MYC;Pten
f/f were
similarly elevated. However, the focal nature of c-MYC expression
in our model means that analysis of total proliferation in the
PbCre4;Z-MYC;Pten
f/f prostates may not be an accurate measure of
the proliferation in foci of c-MYC+;Pten-null cells. To overcome
this, we performed double staining for c-MYC and phospho-
histone H3. As shown in Figure 5B, double mutant (c-MYC+;Pten-
null) cells were more proliferative than single mutant (Pten-null)
cells within the same prostate glands. Furthermore, double mutant
cells are histologically distinct from adjacent single mutant cells.
The double mutant cells are of higher pathological grade with
larger nuclei, high nuclear:cytoplasmic ratios, hyperchromatic
nuclei with prominent chromocenters, focal chromatin clearing
and prominent single or sometimes multiple nucleoli (Figure 5C
and Figure S1). In addition, apoptotic and mitotic figures are
prominent. Single mutant (Pten-null) cells on the other hand
showed low nuclear grade with comparatively small and uniform
nuclei, abundant pale cytoplasm and low nuclear:cytoplasmic
ratios. These cells also have inconspicuous nucleoli and the
chromatin is comparatively fine (Figure 5C). These observations
suggest that c-MYC+;Pten-null cells may out-compete Pten-null cells
within the same prostate gland over time. Indeed, analysis of
PbCre4;Z-MYC;Pten
f/f animals showed that at early ages, c-MYC
expression was focal within glands, but in older mice, lesions show
uniform c-MYC expression, suggesting clonal expansion of c-
MYC-positive cells in a time-dependent manner (Figure 5D).
Pten loss does not protect c-MYC overexpressing
prostate cells from apoptosis
Analysis of apoptosis by staining for activated Caspase 3 shows that
control and PbCre4;Pten
f/+ prostates had low levels of apoptosis,
consistent with their normal histology, while focal expression of c-
MYC in PbCre4;Z-MYC prostates modestly increased apoptosis
Author Summary
In most human cancers, mutations are thought to arise in a
single cell or few cells surrounded by their unaffected
neighbors. Expansion of mutant cells can then allow the
accumulation of additional mutations. The cell–cell inter-
actions that may occur between mutant and unaffected
cells or between cells with distinct mutations during
tumorigenesis have not been well studied due to the lack
of suitable in vivo models. To help fill this gap, we
generated and characterized transgenic mice in which the
oncogene c-MYC is activated focally in prostate epithelial
cells. We have also analyzed mice in which prostate
epithelial cells with two mutations (c-MYC overexpression
and loss of Pten tumor suppressor) are found next to cells
with a single mutation (loss of Pten). Although loss of Pten
in the prostate is tumorigenic, it also activates a cellular
senescence response which restrains further tumor pro-
gression. We found that concurrent c-MYC expression
suppressed the senescence response in Pten-null cells in
favor of apoptosis. c-MYC+;Pten-null cells proliferated
faster than Pten-null cells in the same glands, with the
net result that c-MYC+;Pten-null cells outcompete Pten-null
cells. Our results demonstrate the utility of accurate
models to mimic the heterogeneous and incremental
nature of human prostate carcinogenesis.
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apoptosis in several tissues, this depends on many variables including
the level of c-MYC overexpression and the ‘‘tissue context’’ [28,29].
The levels of apoptosis seen in PbCre4;Z-MYC prostates are consistent
with increased cell turnover due to enhanced proliferation. Pten-null
prostates also had increased rates of apoptosis, and c-MYC
overexpression further enhanced this effect (Figure 6A). These results
were surprising as Pten loss is known to activate pro-survival
pathways. Therefore, we sought to determine if apoptosis is increased
i nH G P I N / c a n c e rc e l l st h a th a v el o s tP t e ne x p r e s s i o ni no u r
PbCre4;Z-MYC;Pten
f/+ mice. Double staining for Pten and activated
Caspase 3 and quantitative analysis indicated higher rates of
apoptosis in Pten-negative cells compared to Pten-positive cells
(Figure 6B). Thus Pten loss does not protect prostate cells from
apoptosis due to c-MYC overexpression.
In addition to Akt, the c-Jun N-terminal kinase (Jnk) pathway
is known to be activated in Pten-deficient cells and tumors
[30,31]. We confirmed that the Jnk pathway is activated in both
Pten-null and c-MYC-overexpressing/Pten-null prostates by im-
munohistochemistry for phospho-Jnk (Figure S2A). Since Jnk is
well known to have the ability to activate apoptosis, cell survival
and proliferation depending on cellular signal stimuli and
cellular contexts [32], we asked if increased Jnk activity sensitizes
Pten-deficient cells to apoptosis. We used small hairpin RNA to
stably downregulate PTEN in the benign human prostatic cell
line RWPE1. However, treatment with the Jnk inhibitor
(SP600125) led to an increase in apoptosis in PTEN knockdown
cells in a dose-dependent manner, suggesting that PTEN loss-
induced Jnk activity is anti-apoptotic, rather than pro-apoptotic
(Figure S2).
Figure 1. c-MYC expression in PbCre4;Z-MYC mouse prostate is mosaic and uncoupled from androgen regulation. (A) LacZ stain depicts
mosaic expression of transgene in Z-MYC prostate. Arrows indicate LacZ-positive cells. The frequency of transgene-expressing cells varied depending
on glands and lobes, but quantitative analysis indicated that overall, LacZ-positive cells comprised ,17% of the epithelial cells in any LacZ-positive
gland (a) and (b). (c) shows schematic representation of Cre excision of the Z-MYC construct. c-MYC expression is activated and regulated by CMV/
Actin promoter after Cre-excision. (B) Immunostaining verifies sporadic c-MYC expression in PbCre4;Z-MYC prostate epithelium of intact mouse (a) and
17 weeks after castration (b). (C) c-MYC colocalizes with cytokeratin 8 (CK8) (a) but not with p63 (b) in PbCre4;Z-MYC mouse prostates.
doi:10.1371/journal.pgen.1000542.g001
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PLoS Genetics | www.plosgenetics.org 3 July 2009 | Volume 5 | Issue 7 | e1000542Figure2. Pathologyof PbCre4;Z-MYC andcompoundc-MYC/Pten mutant mice. (A)Hematoxylin andeosin (H&E)–stained prostate sections were
analyzed and the summary of the pathological grading is shown. (N,number of mice analyzed). (B) Representative images of H&E-stained sections show
benign glands in control (a), focal LGPIN in PbCre4;Z-MYC (boxed region in b and higher magnification in (c), focal HGPIN lesion in PbCre4;Z-MYC (d),
benign glands in PbCre4;Pten
f/+ (e), focal HGPIN lesions in PbCre4;Z-MYC;Pten
f/+ (boxed regionin f andhigher magnification in g) andfocal micro-invasive
cancer lesion (arrow)in PbCre4;Z-MYC;Pten
f/+ (h). Scale bars: 100 mm in (a,b,e,f) and50 mm in (c,d,g,h). (C) c-MYCandsmooth muscle actin (SMA) staining.
Arrows in (c) indicate focal areas of disruption of SMA (micro-invasion) in PbCre4;Z-MYC;Pten
f/+ prostate. Scale bar: 100 mm.
doi:10.1371/journal.pgen.1000542.g002
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cells from senescence to apoptosis
It is known that Pten loss can activate the p53 pathway in the
prostate cells and activation of the p53 pathway could lead to
either senescence or apoptosis depending on the particular p53
target genes induced [13,17,18,33]. We therefore sought to
examine activation of the p53 pathway in our c-MYC/Pten model
and to determine whether concurrent c-MYC expression alters the
p53 response. We observed induction of p53, its targets p21
cip1
and PUMA in Pten-null prostates (Figure 7A). However, while p53
and PUMA were induced in c-MYC-overexpressing Pten-null
prostates, p21
cip1 expression was not (Figure 7A), consistent with
the notion that c-MYC represses p21
cip1 expression [21]. Similar
results were obtained in RWPE-1 cells (Figure 7B). While p53 and
p21
cip1 were induced upon PTEN knockdown, c-MYC overex-
pression repressed p21
cip1 expression (Figure 7B). We hypothe-
sized that in Pten-deficient cells with activation of the p53 pathway,
repression of p21
cip1 by c-MYC may switch the senescent response
to apoptosis. Indeed, using immunofluorescence, we found that in
PbCre4;Z-MYC;Pten
f/f prostates, p16
ink4a expression (a marker of
senescence) is mainly localized to c-MYC-negative cells while
apoptosis (activated Caspase 3) is found predominantly among c-
MYC-positive cells (Figure 7C). Thus Pten-deficiency activates the
p53/p21
cip1 pathway but concurrent c-MYC overexpression shifts
the output of the pathway from senescence to apoptosis at least
partly by repressing p21
cip1.
Discussion
Human prostate carcinogenesis is focal, random, and incre-
mental, but current mouse models do not faithfully recapitulate
this. Consequently, the competitive/cooperative interactions that
may occur between mutant and normal cells during the early
stages of tumorigenesis have not been well studied. The model
described here exploits the stochastic expression of a ‘‘Cre-
activatable’’ c-MYC transgene (Z-MYC) to induce c-MYC
expression in isolated cells surrounded by normal cells. As
illustrated by our studies when the Z-MYC mouse is crossed with
prostate-specific Pten deletion, the focal nature of c-MYC
Figure 3. Time-dependent increase in c-MYC–expressing cells without discernible histopathology in a subset of PbCre4;Z-MYC mice.
(A–C) H&E images demonstrate absence of histopathological abnormalities in PbCre4;Z-MYC prostates at various ages. (D–F) Adjacent sections subject
to immunofluorescent staining for c-MYC demonstrate the numbers of c-MYC–overexpressing cells increase in a time-dependent manner. (G) The
number of c-MYC–positive cells in any c-MYC–positive gland was quantitated based on the immunostaining shown in (D–F). N=3–4 prostate
samples per group. *p,0.05.
doi:10.1371/journal.pgen.1000542.g003
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alterations within the same prostate gland.
Our studies have yielded several insights. First, focal expression
of c-MYC in prostate luminal epithelial cells, even though driven
by the CMV enhancer/beta actin promoter, results in remarkably mild
pathology with many mice showing histologically normal prostates
and a subset of mice demonstrating LGPIN lesions. These results
imply a remarkable tolerance of luminal epithelial cells to c-MYC
expression. We showed that the acquisition of additional genetic
mutations is essential for the appearance of discernable pathology
by the fact that introduction of Pten heterozygosity into these
animals resulted in cooperativity, with the development of
HGPIN/cancer lesions which in all cases were associated with
loss of Pten protein expression from the wild type allele. These
observations highlight an important point about c-MYC-express-
ing cells in histologically ‘‘normal’’ glands, as may occur in tumors
and tissues with ‘‘field cancerization’’ [26,34–37] in that the
overexpression of c-MYC in histologically ‘‘normal’’ cells may
facilitate the acquisition of secondary mutations. Although it
remains to be established whether loss of Pten expression is due to
genetic, epigenetic or post-transcriptional control, c-MYC expres-
sion may facilitate acquisition of secondary mutations by
increasing cell turnover and/or genomic instability [38,39].
Our PbCre4;Z-MYC;Pten
f/f mice allowed us to examine the
behavior of prostate cells with distinct mutations in the same
prostate. c-MYC expression clearly confers an additional prolifer-
ative advantage to Pten-null prostate cells, allowingc-MYC+;Pten-null
cells to outcompete Pten-null cells. However, Pten deficiency did not
alleviate apoptosis in c-MYC+;Pten-null cells. This may appear
surprising in light of the well-known, pro-survival effect of Pten loss
[40] and a report that Pten loss decreased the apoptosis engendered
by the inactivation of retinoblastoma (pRb) family proteins by a
truncated SV40 T large antigen in the mouse prostate [41].
Nevertheless, previous studies of mice with conditional deletion of
Pten in the prostate and testicular germline cells have noted an
increased rate of apoptosis upon Pten deletion [10,11,42] and
Radziszewska et al recently showed that deleting Pten concurrently
with c-MYC activation in pancreatic beta cells led to increased
apoptosis [43]. Furthermore, Pten deficiency has been reported to
activate the p53 pathway leading to senescence [13,18,44] as well as
to sensitize cells to ROS-induced apoptosis [17].
Based on our studies and published reports, we propose the
following model of cooperativity between c-MYC and Pten in
prostate cancer (Figure 7D): Overexpression of c-MYC initiates
tumorigenesis by facilitating loss of Pten. The latter leads to the
activation of the p53 pathway, which can result in either
senescence or apoptosis depending on the predominant Trp53
target genes induced (i.e. cell cycle arrest genes e.g. p21
cip1 versus
pro-apoptotic genes e.g. PUMA, Bax etc.). The expression of c-
MYC drives cells down the apoptotic pathway as it selectively
represses the cell cycle arrest-inducing target gene p21
cip1.
To summarize, we report a new Cre-dependent prostate cancer
mouse model that reflects the focal, random and incremental
nature of human prostate carcinogenesis. We show that focal c-
MYC expression cooperates with Pten heterozygosity to promote
tumor progression due to the selection of cells with loss of Pten
expression. In addition, cells mutant for both c-MYC and Pten
outcompete single Pten-mutant cells within the same prostates
although Pten-deficiency sensitizes cells to apoptosis that is
associated with activation of the p53 pathway and exacerbated
Figure 4. Focal loss of Pten expression in PIN lesions of PbCre4;Z-MYC;Pten
f/+ mouse prostate. In focal PIN lesion (arrows), Pten protein
expression is lost and phosphorylation of Akt and Foxo1 increased.
doi:10.1371/journal.pgen.1000542.g004
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focal oncogene activation to study the interactions between cell
populations with different genetic alterations in tumorigenesis.
Materials and Methods
Animals
Z-MYC, PBCre4 and Pten
f/f mice have been described [24,25,45].
Female Z-MYC mice (B6/129) were bred to male PbCre4 mice (B6)
obtained from MMHCC, Frederick, to generate PbCre4;Z-MYC
offspring and littermate controls. Pten
f/f mice (B6/129) were obtained
from The Jackson Laboratory. To generate compound mutant mice,
we generated PbCre4;Pten
f/+ males and Z-MYC;Pten
f/+ females which
were further bred to obtain PbCre4;Z-MYC, PbCre4;Pten
f/f, PbCre4;Z-
MYC;Pten
f/+ and PbCre4;Z-MYC;Pten
f/f offspring for experiments as
well as their littermate controls. Animal care and experiments were
carried out according to the protocols approved by the Institutional
Animal Care and Use Committees at Vanderbilt University.
Figure 5. c-MYC expression increases the proliferation and tumorigenicity of Pten-deficient cells. (A) Proliferation was determined by
analysis of phospho-histone H3 staining. (B) Phospho-histone H3 index in c-MYC-positive or c-MYC-negative cells in PbCre4;Z-MYC;Pten
f/f prostates.
Inset: double staining shows colocalization of phospho-histone H3 with c-MYC in PbCre4;Z-MYC;Pten
f/f prostate. N=3–4 mice per group. *p,0.05,
**p,0.005, ****p,0.01. (C) c-MYC staining identifies MYC-expressing cells next to MYC-negative cells in the same gland of PbCre4;Z-MYC;Pten
f/f
mouse prostate. An adjacent H&E-stained section is also shown. Note distinct, higher grade pathology of c-MYC+ cells. Scale bar: 50 mm. (D) c-
MYC+;Pten-null cells outcompete Pten-null cells. Prostates from 10-week-old and 28-week-old PbCre4;Z-MYC;Pten
f/f mice were stained for c-MYC and
smooth muscle actin. At 10 weeks, c-MYC expression is focal; at 28 weeks, it is uniform. Arrows indicate discontinuity of smooth muscle actin (focal
micro-invasion). Scale bar: 100 mm.
doi:10.1371/journal.pgen.1000542.g005
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Beta-galactosidase staining followed by counterstaining with
nuclear fast red was performed as described [24].
Histology and immunohistochemistry
Tissues were prepared for histopathological analysis as described
[46], and slides were reviewed by IEA based on published criteria
[47]. Immunohistochemical analyses were performed as described
[46]. The following antibodies were used, in some cases with
Tyramide Signal Amplification (TSA; Perkin Elmer): anti-activated
Caspase 3 (rabbit, 1:500, Cell Signaling), anti-phospho-histone H3
(rabbit, 1:500, Upstate), anti-phospho-Akt (rabbit, 1:100, Cell
Signaling), anti-phospho-Foxo1 (rabbit, 1:50, Santa Cruz), anti-c-
MYC (rabbit, 1:15,000 with TSA, Santa Cruz), anti-Pten (rabbit,
1:200 with TSA, Cell Signaling), anti-cytokeratin 8 (mouse, 1:2000,
Sigma), anti-p63 (PIN Cocktail, Biocare Medical), anti-p53 (rabbit,
1:5000 with TSA, Santa Cruz), anti-p21 (mouse, 1:50, Santa Cruz),
anti-smooth muscle actin (mouse, 1:2000, Sigma), anti-p16 (rabbit,
1:1000, Santa Cruz), anti-Puma (rabbit, 1:200, Cell Signaling) and
anti-phospho-Jnk antibody (rabbit, 1:100, Cell Signaling). For
double immunofluorescenct stains, c-MYC or Pten detected by 1
st
primary antibodies were amplified by TSA system (green,
Fluorescein). Alexa Fluor 594 (red)-labeled 2
nd secondary antibodies
(Molecular Probes) were used to detect 2
nd primary antibodies (anti-
cytokeratin 8, anti-p63, anti-smooth muscle actin, anti-phospho-
histone H3, anti-p16 and anti-activated Caspase 3). Nuclear stain
(DAPI) and sample mounting were performed using Vectashield
mounting medium (Vector Laboratories).
Proliferation and apoptosis assay
At least 500 cells per sample were counted and quantitated after
immunohistochemistry for phospho-Histone H3 and activated
Caspase 3, respectively. N=3–4 prostate samples from 9–15 week-
old mice per group.
Cell lines
RWPE-1, benign human prostate epithelial cell line (ATCC)
was cultured in keratinocyte serum-free media supplemented with
bovine pituitary extract and EGF (Invitrogen). We used lentiviral-
mediated gene transfer to generate PTEN knockdown/c-MYC
overexpressing cells. 293FT packaging cells were plated on 10 cm
culture dishes and transfected with PTEN shRNA construct/
pLKO.1 vector control (Sigma) or the c-MYC construct/FM-1
vector control along with vesicular stomatitis virus glycoprotein
(VSVG) envelope plasmid and delta 8.9 packaging plasmid to
produce lentivirus. The FM-1 vector was obtained from J.
Milbrandt [48] and was used to clone in human c-MYC cDNA.
Three days after transfection, medium containing viral particles
was collected and added to RWPE-1 for infection with polybrene
(8 mg/ml). 24 hours post infection, medium was changed and
another 24 hours later puromycin (1 mg/ml) was added for
selection of sh-Pten/pLKO.1 cells. YFP-positive c-MYC/FM-1
cells were sorted by flow cytometry.
Western blot analyses
These were performed as described [49] using the following
antibodies: anti-Pten (mouse, 1:1000, Cell signaling), anti-phospho-
Akt (rabbit, 1:2000, Cell signaling), anti-total Akt (rabbit, 1:2000,
Cell signaling), anti-c-MYC (mouse, 1:500, Santa Cruz), anti-p53
(mouse, 1:1000, Santa Cruz), anti-p21(mouse, 1:1000, Santa Cruz)
and anti-beta-actin antibody (goat, 1:1000, Santa Cruz).
Jnk inhibitor treatment and immunocytochemistry for
activated Caspase 3
Coverslips were placed on the 24-well plates and 300,000 control
or Pten knockdown RWPE-1 cells were plated on the coverslips.
Next day, cellsweretreatedwithJnk inhibitor(SP600125) orvehicle
(DMSO) at 0, 10 or 50 mM for one hour. Then cells were washed
with phosphate buffered saline and supplement-free medium was
added to induce apoptosis. After 48 hours, immunocytochemistry
for activated Caspase 3 was performed and apoptosis was
quantitated from triplicate data per group.
Statistical analyses
We compared groups by using t-test. Values are considered
statistically significant at P,0.05. Quantitative variables are
Figure 6. Analysis of apoptosis in c-MYC/Pten compound mutant mice. (A) Apoptosis was analyzed by staining for activated Caspase 3. (B)
Sections from PbCre4;Z-MYC;Pten
f/+ prostates were doubly stained for activated Caspase 3 and Pten, and the number of apoptotic cells was
quantitated in Pten-positive and Pten-negative epithelial cells. N=3–4 mice per group. *p,0.05, **p,0.005, ***p,0.001 and ****p,0.01.
doi:10.1371/journal.pgen.1000542.g006
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PLoS Genetics | www.plosgenetics.org 8 July 2009 | Volume 5 | Issue 7 | e1000542Figure 7. c-MYC and p53 pathway status in c-MYC/Pten mutant prostate cells. (A) Immunohistochemistry for p53, p21 and Puma. Prostate
sections from mice of the indicated genotypes were stained with the indicated antibodies and nuclei were counterstained with hematoxylin. Positive
cells (brown) are indicated by red arrows. (B) Western blots show expression of the indicated proteins in RWPE-1 cells expressing c-MYC, PTEN
knockdown, or control vectors (FM-1, pLKO.1). PTEN and phospho-Akt (pAkt) blots confirm efficiency of PTEN knockdown. (C) Double
immunofluorescent stains for c-MYC/p16 and c-MYC/activated Caspase 3 in PbCre4;Z-MYC;Pten
f/f prostates. Scale bar: 100 mm. (D) Model of
interactions between c-MYC and Pten with the p53 pathway in c-MYC–initiated prostate cancer. Focal c-MYC overexpression leads to LGPIN and
facilitates loss of Pten leading to HGPIN/invasive cancer. Activation of the p53 pathway due to Pten loss could lead to senescence or apoptosis. c-MYC
expression is proposed to shift this response towards apoptosis by repressing p21 expression.
doi:10.1371/journal.pgen.1000542.g007
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Supporting Information
Figure S1 Histopathology of PbCre4;Pten
f/f and PbCre4;Z-MYC;P-
ten
f/f tumors at different ages. PbCre4;Z-MYC;Pten
f/f mice show
higher grade lesions. Scale bars: 100 mm and 50 mm in insets:
higher magnifications.
Found at: doi:10.1371/journal.pgen.1000542.s001 (6.19 MB TIF)
Figure S2 Jnk is activated in Pten-deficient cells and is anti-
apoptotic. (A) Phospho-Jnk expression is apparent in PbCre4;Pten
f/f
and PbCre4;Z-MYC;Pten
f/f prostates (brown). (B) Apoptosis increas-
es in Pten-knockdown RWPE-1 cells when treated with Jnk
inhibitor (SP600125). (C) Western blots show that Pten knockdown
is efficient in PTEN-shRNA-infected RWPE-1 cells. Immunoflu-
orescence images represent increased apoptosis in PTEN-knock-
down cells (red, activated Caspase 3). Nuclei were stained blue.
*p,0.01.
Found at: doi:10.1371/journal.pgen.1000542.s002 (6.79 MB TIF)
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